Amicus brief of the Committee for Justice filed in Epic v. Google antitrust appeal argues that the lower court injunction violates longstanding antitrust precedent, will result in irreparable harm and is against the public interest.

Europe’s campaign to undermine American tech is finally getting the attention it deserves. Last week, the House Judiciary Committee held a hearing examining how EU laws like the Digital Services Act (DSA) and Digital Markets Act (DMA) are being used to censor speech, punish U.S. companies, and tilt digital markets in favor of European firms.

Amicus brief of the Committee for Justice filed in Epic v. Google antitrust appeal argues that the opinion represents a fundamental break from Supreme Court precedent.

The ruling represents an extreme departure from settled antitrust law. The injunction does not merely prohibit unlawful conduct—it compels Google to open the Play Store it built through years of investment to competitors for free, to distribute its entire app catalog to rival stores, and even to carry those rival stores within its own platform.

The Committee for Justice applauds the committee for allocating $37 million below the 2025 FTC appropriations level.

Arizona Attorney General Kris Mayes’ letter demanding Attorney General Pam Bondi to protect renters from market manipulation argues the Department of Justice should intervene in the housing pricing software market—the exact opposite of what the government should do when it comes to antitrust policy. Imploring Bondi to continue litigating a premature lawsuit the Biden administration initiated against the artificial intelligence-driven company RealPage may be well-intentioned f

The Committee for Justice writes in support of the FY2025 Appropriations Bill’s provisions related to the Federal Trade Commission (FTC).

One particular area that enchants the Khan FTC is the nexus of antitrust and intellectual property.

CFJ's 5th Circuit amicus brief opposes the FTC’s attempt to block a merger between Illumina and Grail, maker of a breakthrough cancer test.